Stabilization of EGLN3 by USP9X Contributes to Antineoplastic Function in Cholangiocarcinoma

Weiqian Chen(Wenzhou Medical University), Jiansong Ji(Lishui University), Jianfei Tu(Lishui Central Hospital), Chunmiao Chen(Wenzhou Medical University), Lin Shen(Peking University), Junsoo Song(Lishui Central Hospital), Siyu Liu(Tianjin University of Commerce), Jinyu Zhu(Nanjing University of Chinese Medicine), Shiji Fang(Wenzhou Medical University), Liyun Zheng(Nanchang University), Rongfang Qiu(Lishui Central Hospital), Fazong Wu(Wenzhou Medical University), Bufu Tang(Fudan University), Zhongwei Zhao(Wenzhou Medical University), Yang Gao(HOPE Clinic)
Research Square
December 21, 2020
10.21203/rs.3.rs-130887/v1
Cited by 0

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412